18P: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial
作者
Nicolas Girard,D. Ross Camidge,J. Bar,H. Horinouchi,J.W. Goldman,Nathalie Daaboul,Cissi Liu,I. Cicin,Nuran Katgı,Alona Zer,T-E. Ciuleanu,N. Reinmuth,David Planchard,Aaron Scott Mansfield,Shobhit Baijal,Nan Zhang,Shiven B. Patel,M.S. Xia,C. Ratajczak,S. Lu